Ono Pharmaceutical, Dainippon Sumitomo Pharma to Enter into Joint Development and Marketing Agreement for Limaprost Alfadex, Oral PGE1 Derivative.Tokyo, Japan, Dec 6, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Ono Pharmaceutical and Dainipopn Sumitomo Pharma jointly announced on December 6 that they have singed a joint development and marketing agreement for limaprost alfadex, an oral prostaglandin E Prostaglandin E is a family of naturally occurring prostaglandins. Types include:
1. pertaining to circulation, particularly that of the blood. 2. containing blood. cir·cu·la·to·ry n. 1. disturbance. Under the agreement terms, the two companies aim to obtain approval for an additional indication of limaprost alfadex, namely the treatment of cervical spondylosis cervical spondylosis Degenerative disease of the neck vertebrae. Compression of the spinal cord and cervical nerves by narrowing of spaces between vertebrae causes radiating neck or arm pain and stiffness, restricted head movement, headaches, spastic paralysis, and arm and . Currently, limaprost alfadex is marketed by the two companies: OPALMON Tablet by Ono Pharmaceutical and PRORENAL Tablet by Dainippon Sumitomo. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion